SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Mast Therapeutics,
Inc. (NYSE MKT: MSTX) today announced that the Company's Chief
Executive Officer, Brian M. Culley,
will present at the Cowen & Co. 34th Annual
Healthcare Conference on Monday, March 3,
2014 at 4:50 p.m. Eastern time
at The Boston Marriott Copley Place Hotel in Boston.
Interested parties can access a live audio webcast and slide
presentation on the Mast Therapeutics web site at
www.masttherapeutics.com. An archived presentation will be
available on the web site for 30 days.
About Mast Therapeutics
Mast Therapeutics, Inc. is a
publicly traded biopharmaceutical company headquartered in
San Diego, California. The Company
is leveraging the MAST (Molecular Adhesion and Sealant Technology)
platform, derived from over two decades of clinical, nonclinical
and manufacturing experience with purified and non-purified
poloxamers, to develop MST-188, its lead product candidate, for
serious or life-threatening diseases with significant unmet
needs. MST-188 is a cytoprotective, hemorheologic,
anti-inflammatory and anti-thrombotic agent that has potential
utility in diseases or conditions characterized by microcirculatory
insufficiency (endothelial dysfunction and/or impaired blood
flow).
The Company is enrolling subjects in EPIC, a pivotal phase 3
study of MST-188 in sickle cell disease. In the first quarter
of 2014, the Company plans to initiate a phase 2, clinical proof of
concept study in acute limb ischemia that will evaluate whether
MST-188 improves the effectiveness of existing thrombolytic
agents. The Company also is evaluating development options in
heart failure. More information can be found on the Company's web
site at www.masttherapeutics.com. (Twitter: @MastThera)
Mast Therapeutics™ and the corporate logo are trademarks of Mast
Therapeutics, Inc.
Forward Looking Statements
Mast Therapeutics cautions
you that statements included in this press release that are not a
description of historical facts are forward-looking statements that
are based on the Company's current expectations and assumptions.
Such forward-looking statements include, but are not limited to,
statements regarding the Company's development plans for MST-188 in
acute limb ischemia and heart failure, including the timing of
initiation of any clinical studies. Among the factors that could
cause or contribute to material differences between the Company's
actual results and the expectations indicated by the
forward-looking statements are risks and uncertainties that
include, but are not limited to: delays in the commencement or
completion of clinical studies, including as a result of
difficulties in obtaining regulatory agency agreement on clinical
development plans or clinical study design, opening trial sites,
enrolling study subjects, manufacturing sufficient quantities of
clinical trial material, being subject to a "clinical hold," and/or
suspension or termination of a clinical study, including due to
patient safety concerns or lack of funding; the potential for
institutional review boards or the FDA or other regulatory agencies
to require additional nonclinical or clinical studies prior to
initiation of any planned phase 2 clinical study of MST-188; the
potential that, even if clinical studies of MST-188 in one
indication are successful, clinical studies in another indication
may not be successful; the Company's reliance on contract research
organizations (CROs), contract manufacturing organizations (CMOs),
and other third parties to assist in the conduct of important
aspects of development of MST-188, including clinical studies, and
regulatory activities for MST-188, and that such third parties may
fail to perform as expected; the potential for the Company to
delay, reduce or discontinue current and/or planned development
activities, including clinical studies, partner MST-188 at
inopportune times or pursue less expensive but higher-risk and/or
lower return development paths if it is unable to raise sufficient
additional capital as needed; and other risks and uncertainties
more fully described in the Company's press releases and periodic
filings with the Securities and Exchange Commission. The Company's
public filings with the Securities and Exchange Commission are
available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. Mast
Therapeutics does not intend to revise or update any
forward-looking statement set forth in this press release to
reflect events or circumstances arising after the date hereof,
except as may be required by law.
(Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)
SOURCE Mast Therapeutics, Inc.